Analysts at Aegis initiated coverage on shares of NuVasive Inc. (NASDAQ:NUVA) in a note issued to investors on Wednesday. The firm set a “buy” rating and a $72.00 price target on the medical device company’s stock. Aegis’ target price would suggest a potential upside of 10.04% from the company’s current price.

A number of other research firms also recently issued reports on NUVA. Zacks Investment Research downgraded NuVasive from a “buy” rating to a “hold” rating in a research report on Tuesday, October 25th. Piper Jaffray Cos. reissued an “overweight” rating and set a $70.00 price target on shares of NuVasive in a research report on Thursday, September 1st. TheStreet downgraded NuVasive from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 25th. Barclays PLC increased their price target on NuVasive from $71.00 to $74.00 and gave the stock an “overweight” rating in a research report on Monday, October 10th. Finally, Jefferies Group reissued a “buy” rating and set a $72.00 price target on shares of NuVasive in a research report on Wednesday, October 26th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $66.83.

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Shares of NuVasive (NASDAQ:NUVA) opened at 65.43 on Wednesday. The company has a market capitalization of $3.29 billion, a P/E ratio of 82.61 and a beta of 0.98. NuVasive has a 12-month low of $36.81 and a 12-month high of $69.50. The company has a 50-day moving average price of $62.89 and a 200 day moving average price of $61.83.

NuVasive (NASDAQ:NUVA) last announced its quarterly earnings data on Tuesday, October 25th. The medical device company reported $0.40 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.40. The company had revenue of $239.60 million for the quarter, compared to the consensus estimate of $243.49 million. NuVasive had a return on equity of 10.89% and a net margin of 4.06%. NuVasive’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.35 EPS. On average, equities analysts anticipate that NuVasive will post $1.64 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/30/nuvasive-inc-nuva-now-covered-by-aegis.html.

In related news, EVP Joan Stafslien bought 5,000 shares of the company’s stock in a transaction that occurred on Monday, October 31st. The shares were purchased at an average cost of $59.68 per share, with a total value of $298,400.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael D. Ohalleran bought 4,205 shares of the company’s stock in a transaction that occurred on Monday, October 31st. The shares were bought at an average cost of $59.47 per share, for a total transaction of $250,071.35. The disclosure for this purchase can be found here. 4.70% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of NUVA. Strs Ohio raised its stake in NuVasive by 46.8% in the second quarter. Strs Ohio now owns 6,900 shares of the medical device company’s stock valued at $412,000 after buying an additional 2,200 shares during the period. Smith Asset Management Group LP raised its stake in NuVasive by 7,796.8% in the second quarter. Smith Asset Management Group LP now owns 2,448 shares of the medical device company’s stock valued at $146,000 after buying an additional 2,417 shares during the period. Louisiana State Employees Retirement System raised its stake in NuVasive by 0.5% in the second quarter. Louisiana State Employees Retirement System now owns 22,100 shares of the medical device company’s stock valued at $1,320,000 after buying an additional 100 shares during the period. Bank of Montreal Can bought a new stake in NuVasive during the second quarter valued at approximately $688,000. Finally, LS Investment Advisors LLC raised its stake in shares of NuVasive by 7.8% in the second quarter. LS Investment Advisors LLC now owns 2,097 shares of the medical device company’s stock valued at $125,000 after buying an additional 151 shares during the last quarter.

NuVasive Company Profile

Nuvasive, Inc is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion.

5 Day Chart for NASDAQ:NUVA

Receive News & Stock Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related stocks with our FREE daily email newsletter.